← Oncology Approval Tracker

FDA DECISION ·

Erbitux

cetuximab · ImClone

FDA approvalNew dosing regimenColorectal and head and neck cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Alternative 500 mg/m² intravenous cetuximab dosing every two weeks for labeled KRAS wild-type, EGFR-expressing metastatic colorectal cancer and squamous cell carcinoma of the head and neck.

LAMPGEN ANALYSIS

Why it matters

The decision adds a biweekly administration option for these existing uses.

What research teams should watch

Update infusion templates and align visit frequency with the combination regimen and specimen collection.

PRIMARY RECORDS

Sources